INSPIRE IVF Public Company LimitedSET: IVF🇹🇭 TH

Internal Control · 2025

Internal Control — Board Opinion

Summary of the Board's Opinion on Internal Control

The Company places importance on maintaining an effective internal control system in accordance with the principles of good corporate governance. The emphasis is on operations that are transparent, fair, reliable, and subject to checks and balances that ensure accountability, ultimately serving the best interests of shareholders, employees, customers, business partners, and all stakeholders. The Company has an Audit Committee consisting of three members. Their responsibility is to review the adequacy of the internal control system and to ensure that the Company’s operations comply with the regulations of the Securities and Exchange Commission, the Stock Exchange of Thailand, the Public Limited Companies Act, the Securities and Exchange Act, as well as other relevant rules applicable to the Company and/or its business. This reflects the Company’s commitment to maintaining governance standards, thereby enhancing transparency, building trust, and supporting sustainable business operations in the long term.

Adequacy & Appropriateness of the Internal Control System

Internal Control Framework Used

FrameworkDetail
The Committee of Sponsoring Organizations of the Treadway Commission (COSO)

At the Board of Directors’ Meeting No. 1/2026 held on February 27, 2026, all members of the Audit Committee attended. The Board of Directors reviewed and prepared an assessment of the adequacy of the internal control system, covering all five components of the Committee of Sponsoring Organizations of the Treadway Commission (COSO), namely:

  1. Control Environment

  2. Risk Management

  3. Control Activities

  4. Information & Communication

  5. Monitoring Activities

Based on the assessment, the Board of Directors concluded that the Company has established adequate and effective management and internal control systems. These systems are capable of preventing potential risks and safeguarding against unauthorized or improper use of the Company’s assets. In addition, the internal controls are sufficient to oversee transactions with related parties or those that may involve conflicts of interest. The Board of Directors and management have encouraged employees to recognize the importance of internal control and have ensured that adequate personnel are in place to maintain an appropriate system. The system can be adjusted and improved effectively to align with changing circumstances. This ensures that the Company’s operations achieve the established objectives, comply with applicable laws and regulations, and adhere to the principles of good corporate governance. The Company has clearly defined duties and responsibilities, and has established written rules, regulations, policies, and appropriate authorization procedures. The Audit Committee expressed no differing opinions from those of the Board of Directors.

Internal Control Deficiencies

Number of Deficiencies

MetricCurrent YearPrevious YearTwo Years Ago
Total number of internal control system deficiencies (cases)000

Audit Committee & Auditor Observations

Audit Committee's Opinion Differs from the Board's

No

Auditor Has Observations on Internal Control

Yes

Auditor's Observations

Report on Internal Control and Other Matters from the Audit

The Company’s auditor, Mr. Pot Asawasintrichai from Grin Audit Co., Ltd., who has been approved by the Securities and Exchange Commission (SEC), has reviewed and evaluated the Company’s accounting system and internal control system related to accounting. The objective was to determine the scope of audit work and appropriate audit procedures in order to express an accurate opinion on the financial statements. In the audit of the financial statements for the year ended December 31, 2025, the auditor did not identify any significant deficiencies in accounting internal controls or other matters that could materially affect the financial reporting

Opinion on the Head of Internal Audit

Head of Internal Audit

3160

Audit Committee's Opinion on the Head of Internal Audit

The Audit Committee considered the qualifications of Unique Advisor Co., Ltd. to serve as the Company’s internal auditor for the year and appointed Mr. Kosol Yamleemul as Head of Internal Audit. The Committee determined that he possesses the appropriate education, experience, and training to perform his duties, as well as independence in carrying out his responsibilities. His role is to examine and assess the adequacy of the Company’s internal control system and compliance with established procedures. The internal auditor coordinates with all departments of the Company to monitor improvements to the internal control system in line with recommendations, prepares evaluation and audit reports, and submits them directly to the Audit Committee on a regular and continuous basis. These activities reflect the Company’s commitment to enhancing governance standards, with a focus on transparency, trust, and the protection of the interests of shareholders, employees, customers, business partners, and all stakeholders, thereby supporting stable and sustainable long-term growth. In accordance with its scope of authority, duties, and responsibilities, the Audit Committee has the power, together with management, to evaluate performance, consider merit, and approve the removal, reassignment, or termination of the Company’s Head of Internal Audit.

Appointment, Discharge & Transfer of the Head of Internal Audit

Requires Audit Committee Approval

Yes

Description

The Company appointed Unique Advisor Co., Ltd. (“Internal Auditor”) as the internal auditor, providing recommendations on appropriate internal control systems and continuously monitoring improvements. The appointment was made pursuant to the resolution of the Audit Committee Meeting No. 5/2024 held on Sunday, October 27, 2024, with the scope of work covering the period from Q1/2025 to Q4/2025.

The Audit Committee has considered the qualifications of Unique Advisor Co., Ltd. and Mr. Kosol Yaemleemool and determined that they are suitably qualified to perform the review and assessment of the adequacy of the Company’s internal control system and to report the results to the Audit Committee, with the scope covering the entire internal control system as follows

1) Revenue from sales/services and the cash receipt system

2) General IT controls

3) Human resource management

4) Testing of application controls

5) Follow-up on outstanding audit observations (if any)

6) Laboratory management and inventory management

7) Procurement, expenses, and disbursements

8) Fixed asset management and maintenance

9) Financial management, budgeting, and cash management

10) Testing of application controls

11) Follow-up on outstanding audit observations (if any)

12) Revenue from sales/services and cash receipt system

13) Financial closing and financial statement preparation system

14) Compliance with the Personal Data Protection Act (PDPA)

15) Testing of application controls

16) Follow-up on outstanding audit observations (if any)

17) Enterprise risk management

18) Corporate governance and sustainable development (ESG)

19) Related party transactions

20) Review of the preparation of the “Assessment Form on the Adequacy of the Internal Control System” in accordance with the COSO framework

21) Follow-up on outstanding audit observations (if any)

For the year 2025, the internal auditor conducted four reviews of the internal control system and continuously followed up on corrective actions based on recommendations from the prior year’s internal control reviews. In addition, four internal control review reports were prepared and submitted to the Audit Committee at its meetings.

Related Party Transactions

Has Related Party Transactions

Yes

Counterparties & Transactions

Monetary Unit

1000000

Counterparties with Potential Conflicts

NamePerson / Juristic PersonType of BusinessNature of RelationshipAs of Date (YYYY-MM-DD)
Chanachai JoonjirapornPerson

- Serves as Director in the position of Chairman of the Executive Committee and as an authorized director of the Company

- The company's major shareholder, Mr. Chanachai Joonjiraporn, holds 32.46 percent of the registered paid capital as of December 31, 2025.

2025-12-31T00:00
Miss Kasinee KuldilokePerson

- Serves as Director in the position of Chief Executive Officer and as an authorized director of the Company

- Shareholder of the company, with Ms. Kasinee Kuldiloke holding 6.75 percent of the registered and paid-up capital as of December 31, 2025.

2025-12-31T00:00
Mr. Bandit AnantamongkolPerson

- Authorized director of the Company

- Shareholder of the Company, with Mr. Bandit Anantamongkol holding 4.23 percent of the paid-up registered capital as of December 31, 2025

2025-12-31T00:00
Mr. Santa SrisuparpPerson

- Executive Director and Chief Medical and Nursing Officer of Inspire IVF Public Company Limited

2025-12-31T00:00
I-STUDIOS-D Co.,Ltd.Juristic PersonEngage in the business of providing architectural design, landscape architecture, interior design, and engineering services.
  • Mr. Thitiwat Joonjirapornkul is a director and holds 60 percent of the shares in I-Studio-D Co., Ltd.

  • Mr. Thitiwat Joonjirapornkul is the younger brother of Mr. Chanachai Joonjiraporn.

  • Mr. Thitiwat Joonjirapornkul holds 0.24 percent of the paid-up registered capital of Inspire IVF Public Company Limited as of the Record Date for determining the shareholders entitled to receive dividends on March 14, 2025.

2025-12-31T00:00

Transactions by Counterparty

Transactions
0.0 · Necessity: The Company utilizes the assets of a director (major shareholder) in the conduct of its business · Description: At the end of 2021, the Company adjusted its asset register by writing off assets for which supporting evidence could not be reliably provided for accounting purposes, with a total historical cost of THB 2.59 million. The amount was offset against loans from directors/major shareholders. Following this adjustment, the Company continued to utilize the assets. The assets of the directors/major shareholders currently used by the Company are mostly non-core business assets, such as furniture and decorations, and are of insignificant value. The directors/major shareholders have consented to the Company’s continued use of these assets without charging any value. However, the Company will bear the expenses related to dismantling. · As of yesteryear: 0.0 · Nature of transaction: Transactions in the ordinary course of business and transactions in support of the ordinary course of business · Audit committee opinion: The use of directors’ assets arose from the fact that, in the past, the Company did not have a clearly assigned person responsible for maintaining the asset register and accounting records. Subsequently, the Company corrected the asset register and accounting records and wrote off assets for which reliable supporting evidence could not be provided. The assets that the Company continues to use are mostly furniture and decorations, which are not core business assets and are of insignificant value. Therefore, this does not constitute reliance on core business assets owned by directors/major shareholders. Such transactions occurred out of necessity and for the benefit of the Company. Apart from these past transactions, the Company has since procured the assets required for its business operations without requesting the use of assets owned by directors/major shareholders. · As of year before yesteryear: 0.0
0.0 · Necessity: In May 2023, the Company entered into a hire-purchase agreement for an ultrasound machine valued at THB 1.08 million, with Miss Kasinee Kuldiloke acting as guarantor under the hire-purchase contract for a period of three years, from May 2023 to May 2026, without any remuneration. · Description: Miss Kasinee Kuldiloke has provided a guarantee for the Company · As of yesteryear: 0.0 · Nature of transaction: Transactions involving the provision and receipt of financial assistance, and guarantees with financial institutions · Audit committee opinion: This transaction arose out of necessity in the Company’s business operations, and the requirement by financial institutions for directors to guarantee credit facilities is considered a normal condition. The Company bears no expenses in relation to such guarantees provided by the directors. · As of year before yesteryear: 0.0 · 0.0 · Necessity: In 2020, Miss Kasinee Kuldiloke utilized fertility treatment services, which are part of the Company’s ordinary business. When the Company established its related-party transaction policy in October 2022, the director subsequently paid service fees to the Company at rates comparable to those charged to other customers. Miss Kasinee received fertility treatment services at a fee of THB 4,000 per year. For the annual fee from 2022, she paid THB 8,000 in 2023, THB 4,000 in 2024, and THB 4,000 in 2025, all at rates comparable to those charged to other customers. · Description: Utilized fertility treatment services · As of yesteryear: 0.0 · Nature of transaction: Transactions in the ordinary course of business and transactions in support of the ordinary course of business · Audit committee opinion: The Company provided services to Miss Kasinee Kuldiloke in the ordinary course of its business, with compensation charged at rates comparable to those applied to other customers. This transaction therefore arose from the Company’s ordinary business operations, under normal commercial terms and pricing. It is considered necessary, reasonable, and conducted at prices and conditions comparable to transactions with general third parties. · As of year before yesteryear: 0.0
0.1 · Necessity: Revenue from Wellness services, comprising two packages with a total value of THB 104,000, charged at rates comparable to those applied to other customers. · Description: Utilized Wellness services · As of yesteryear: 0.0 · Nature of transaction: Transactions in the ordinary course of business · Audit committee opinion: The Company provided services in the ordinary course of its business, with compensation charged at rates comparable to those applied to other customers. This transaction therefore arose from the Company’s ordinary business operations, under normal commercial terms and pricing. It is considered necessary, reasonable, and conducted at prices and conditions comparable to transactions with general third parties. · As of year before yesteryear: 0.0
0.33 · Necessity: The Company paid professional medical fees, in addition to salary, to Mr. Santha Srisupap for services relating to oocyte retrieval and embryo transfer. The fees amounted to THB 0.93 million for 2024 and THB 0.33 million for 2025. These fees were paid in accordance with the professional fee structure policy approved by the Board of Directors at Meeting No. 4/2024 on July 9, 2024. · Description: Works for the Company · As of yesteryear: 0.93 · Nature of transaction: Compensation · Audit committee opinion: This transaction arose from the Company’s ordinary course of operations, at a fair price, and does not cause the Company to lose any benefits. · As of year before yesteryear: 0.76
0.13 · Necessity: Office renovation and repair works · Description: The Company engaged I-Studio-D Co., Ltd., in which Mr. Thitiwat Chuljirapornkul, a shareholder of the Company, is also a shareholder and an authorized director of I-Studio-D Co., Ltd., to carry out repair and maintenance works, including replacement of cove ceiling lights and a transformer in the recovery room, Examination Room 1, and the CFO’s office. The total service fee amounted to Baht 12,980. The work has been fully completed and delivered in accordance with the contract as of the end of the first quarter. · As of yesteryear: 0.06 · Nature of transaction: Provide services in the normal course of business · Audit committee opinion: This transaction arose from the company’s normal course of business. The company conducted a price comparison and complied with the procurement regulations of the General Procurement Committee. Therefore, this transaction is considered necessary, reasonable, and consistent with the company’s standard operating practices. The price and terms are comparable to those of transactions carried out with general third parties in accordance with the prescribed regulations. · As of year before yesteryear: 1.09

Policy & Future Trends

Policy, Measures & Approval Process

The Company has established policies and practices for entering into related-party transactions, which are reviewed annually by the Board of Directors. In cases where the Company needs to engage in transactions with persons who may have conflicts of interest or vested interests, measures and approval procedures have been established for related-party transactions and transactions involving the acquisition or disposal of Company assets, in compliance with the requirements of the Securities and Exchange Commission (SEC) and applicable laws, as follows:

1. Transactions in the ordinary course of business and transactions in support of the ordinary course of business. Such transactions must be conducted under normal commercial terms and fair pricing, without transferring benefits, comparable to transactions between the Company and general third parties, or transactions between related parties and general third parties, or transactions of a similar nature with other operators in the same industry. The Company’s policy requires the Audit Committee to review and provide opinions on the rationale and necessity of such transactions on a quarterly basis, and to ensure compliance with the Securities and Exchange Act, relevant rules, notifications, orders, or requirements of the SEC and the Stock Exchange of Thailand, including disclosure requirements for related-party transactions.

2. Other transactions beyond the ordinary course of business and supporting transactions, such as property leases, asset purchases or sales, or financial assistance. The Company’s policy requires the Audit Committee to review and provide opinions on the rationale and necessity of such transactions, and to ensure compliance with the Securities and Exchange Act, relevant rules, notifications, orders, or requirements of the SEC and the Stock Exchange of Thailand, including disclosure requirements for related-party transactions and significant asset acquisitions or disposals. The Company has no policy to provide loans for persons with potential conflicts of interest to conduct business or operate on behalf of the Company, ensuring that decisions to enter into such transactions do not create conflicts of interest and serve the best interests of all shareholders. The Company discloses such related-party transactions in its annual information disclosure form and in the notes to the financial statements audited by the Company’s auditor.

3. The Company will disclose such transactions in accordance with the criteria and procedures prescribed by the SEC.

4. All directors must comply with Section 88 of the Public Limited Companies Act B.E. 2535 (1992), which requires directors to promptly notify the Company in the following cases:
4.1 Having direct or indirect interests in any contract entered into by the Company during the fiscal year, specifying the facts of the contract, the contracting party, and the director’s interest in the contract (if any).
4.2 Holding shares or debentures in the Company or its subsidiaries, specifying the total number of shares or debentures increased or decreased during the fiscal year (if any).

Furthermore, the Company requires major shareholders, directors, and executives to submit information on their related parties to the Company Secretary’s Office, including updates upon any changes, to ensure compliance with procedures governing transactions with major shareholders, directors, executives, or persons related to such parties.

Future Trends in Related Party Transactions

The Company anticipates that, in the future, it may continue to enter into related-party transactions with persons who may have conflicts of interest with the Company. Such transactions must be necessary and beneficial to the Company. For related-party transactions that are in the ordinary course of business and in support of the ordinary course of business under general commercial terms, the Company will comply with its control measures for related-party transactions. Specifically, such transactions shall follow the principles approved by the Board of Directors, as prescribed under the Securities and Exchange Act, and shall strictly adhere to the agreed contracts. Prices and conditions must be clearly defined, fair, and must not result in the transfer of benefits. In cases where related-party transactions require the Audit Committee’s opinion under the rules, regulations, and requirements of the Stock Exchange of Thailand regarding related-party transactions, the Company will seek the Audit Committee’s opinion on the necessity and appropriateness of such transactions.

Contents